Ascendis Pharma A/S
NASDAQ:ASNDBiotechnology
-$0.05 today
- Market cap
- $17.73B
- Beta
- 0.39
- P/E (TTM)
- 24.5
- EPS (TTM)
- $8.21
Volume 0.57M
Average 0.64M
ASND Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Ascendis Pharma A/SNASDAQ: ASND
Financing Cash Flow · Q3 FY2026 · quarter ended Sep 2026
Financing cash flow turns negative
Q3 FY2026 financing cash flow was -€37.35M, compared with €38.85M a year earlier. Trailing-twelve-month financing cash flow was -€113.07M. Over 3 fiscal years it compounded at -55.5% a year.
Context
- Financing cash flow amounted to 5.0% of revenue in FY2025, down 117.0 pp from a year earlier.
- Financing cash flow increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly financing cash flow holds near -€37.35M or moves back toward the trailing-twelve-month quarterly average of -€28.27M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
EUR · from the cash flow
- Latest · FY2025
- 34.89M EUR
- Year-over-year change
- -92.1%
- 4-year CAGR
- -43.9%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 34.89M | -92.1% |
| FY2024 | 2024-12-31 | 443.93M | +230.6% |
| FY2023 | 2023-12-31 | 134.29M | -66.2% |
| FY2022 | 2022-12-31 | 396.77M | +12.9% |
| FY2021 | 2021-12-31 | 351.39M | — |
Financing Cash Flow vs competitors
How ASND compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -505.3% is the lowest of 11, against a peer median of +10.0%.
- Financing cash flow amounts to 9.4% of revenue for ASND, versus a peer median of 70.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $3.53T USD | +8275006.7% | +31.5% | 343.9% | |
| LTM Jun 2026 | $2.22B USD | +414.7% | — | 70.4% | |
| LTM Mar 2026 | $477.84M USD | +19.6% | -1.6% | 71.4% | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $189.81M USD | +0.4% | +60.3% | — |
| LTM Mar 2026 | $180.34M USD | +37.9% | +28.0% | 562.2% | |
| LTM Jun 2026 | $123.96M USD | -91.4% | +6.3% | 10.9% | |
| LTM Sep 2026 | €113.07M EUR | -505.3% | -55.5% | 9.4% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $80.93M USD | -73.5% | -61.7% | 84.1% |
| LTM Jun 2026 | $78.91M USD | -53.1% | +133.6% | 9.5% | |
| LTM Sep 2026 | $60.4M USD | -83.5% | -45.3% | 1.6% | |
| LTM Mar 2026 | $5.69M USD | +363.0% | -55.3% | 1.8% | |
| Peer median (excluding ASND) | — | +10.0% | +6.3% | 70.4% | |
Competitors are the stored peer set for ASND. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (383.58M) | (583.19M) | (481.45M) | (378.08M) | (219.03M) |
| Depreciation & Amortization | 15.39M | 17.96M | 18.91M | 17.71M | 17M |
| Deferred Income Tax | (367K) | 5.38M | 7.3M | 4.84M | 3.21M |
| Stock-Based Compensation | 66.83M | 64.18M | 66.66M | 95.51M | 0 |
| Change in Working Capital | (47.72M) | (12.47M) | (99.79M) | (107.16M) | 68.16M |
| Accounts Receivables | (6.66M) | (11.53M) | (32.77M) | (118.61M) | 14.97M |
| Inventory | (75.41M) | (55.27M) | (78.26M) | (86.68M) | (5.69M) |
| Accounts Payables | 0 | 0 | 0 | 0 | (9.96M) |
| Other Working Capital | 34.34M | 54.33M | 11.25M | 98.13M | 68.84M |
| Other Non-Cash Items | (68.21M) | 12.45M | 21M | 60.98M | 182.44M |
| Operating Cash Flow | (417.65M) | (495.7M) | (467.36M) | (306.2M) | 51.77M |
| Capital Expenditures | (24.23M) | (14.49M) | (2.44M) | (1.43M) | (8.15M) |
| Acquisitions (Net) | (10.19M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (226.04M) | (213.84M) | 0 | 0 | 0 |
| Sales of Investments | 149.88M | 280.53M | 0 | 7.35M | 0 |
| Other Investing Activities | (530K) | 9.54M | 288.92M | 950K | 0 |
| Investing Cash Flow | (110.58M) | 61.73M | 286.47M | 6.88M | (8.15M) |
| Debt Repayment | (6.43M) | 496.93M | 125.82M | 122.79M | (21.09M) |
| Common Stock Issued | 367.88M | 0 | 0 | 309.91M | 83.64M |
| Common Stock Repurchased | (21.61M) | (105.31M) | (1.81M) | 0 | (16.71M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 11.54M | 5.15M | 10.29M | 11.22M | (10.95M) |
| Financing Cash Flow | 351.39M | 396.77M | 134.29M | 443.93M | 34.89M |
| Effect of Forex Changes | 38.59M | 35.69M | (6.01M) | 22.77M | 44.13M |
| Net Change in Cash | (138.25M) | (1.5M) | (52.6M) | 167.38M | 122.65M |
| Free Cash Flow | (441.88M) | (510.19M) | (469.8M) | (307.62M) | 43.62M |
Ascendis Pharma A/S
NASDAQ:ASND
Intrinsic Alpha fair value
Locked
Current Price
$270.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.